Promoting Natural Repair of Spinal Cord Injury and Restoration of Central Nervous System Connectivity with Mike Kelly NervGen
Release Date: 06/28/2024
Empowered Patient Podcast
Mike Kelly, CEO of NervGen Pharma, discusses the company's vision to build a startup biotech focused on repairing the central nervous system, helping patients regain function, not just slowing progression. Their first product, NVG-291, is currently in clinical trials for spinal cord injury. The drug candidate aims to promote natural repair by targeting molecules called CSPGs that inhibit nerve growth and repair. NerveGen is also developing NVG-300 for other indications such as stroke, ALS, MS, and Alzheimer's. He draws parallels between his previous experience developing the Narcan Nasal...
info_outline Promoting Natural Repair of Spinal Cord Injury and Restoration of Central Nervous System Connectivity with Mike Kelly NervGenEmpowered Patient Podcast
Mike Kelly, CEO of NervGen Pharma, discusses the company's vision to build a startup biotech focused on repairing the central nervous system, helping patients regain function, not just slowing progression. Their first product, NVG-291, is currently in clinical trials for spinal cord injury. The drug candidate aims to promote natural repair by targeting molecules called CSPGs that inhibit nerve growth and repair. NerveGen is also developing NVG-300 for other indications such as stroke, ALS, MS, and Alzheimer's. He draws parallels between his previous experience developing the Narcan Nasal...
info_outline Developing Recurring Revenue Health and Wellness Products and Services to Optimize Patient Experience and Build Loyalty with Matt Cronin House of Kaizen TRANSCRIPTEmpowered Patient Podcast
Matt Cronin, Founding Partner of House of Kaizen, discusses how patients' changing healthcare expectations are shaped by their experiences with products and services such as Netflix and Amazon Prime. Consumers now expect a longer-term relationship and personalized experiences with their healthcare providers. House of Kaizen emphasizes the importance of building better customer experiences in health and wellness to improve health outcomes and create more value for businesses. In the age of AI, the importance of trust and brand reputation is paramount. Healthcare providers, as the trusted...
info_outline Developing Recurring Revenue Health and Wellness Products and Services to Optimize Patient Experience and Build Loyalty with Matt Cronin House of KaizenEmpowered Patient Podcast
Matt Cronin, Founding Partner of House of Kaizen, discusses how patients' changing healthcare expectations are shaped by their experiences with products and services such as Netflix and Amazon Prime. Consumers now expect a longer-term relationship and personalized experiences with their healthcare providers. House of Kaizen emphasizes the importance of building better customer experiences in health and wellness to improve health outcomes and create more value for businesses. In the age of AI, the importance of trust and brand reputation is paramount. Healthcare providers, as the trusted...
info_outline Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni Kura Oncology TRANSCRIPTEmpowered Patient Podcast
Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene...
info_outline Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni Kura OncologyEmpowered Patient Podcast
Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene...
info_outline New Landscape for Controlling Obesity and Lowering Incidence of Related Diseases with Dr. Steffen-Sebastian Bolz Aphaia Pharma TRANSCRIPTEmpowered Patient Podcast
Dr. Steffen-Sebastian Bolz, Chief Scientific Officer of Swiss-based Aphaia Pharma, shines a light on the excitement around weight loss drugs due to the discovery that GLP-1 agonists and points out the shift in the perception of obesity as a root cause of various health issues. Aphaia Pharma's approach involves stimulating hormone production in the small intestine by reinvigorating the mechanism that has become dormant due to the ingestion of highly refined foods. The company is also exploring the effects of the circadian rhythm on weight loss and maintaining a healthy weight. Steffen...
info_outline New Landscape for Controlling Obesity and Lowering Incidence of Related Diseases with Dr. Steffen-Sebastian Bolz Aphaia PharmaEmpowered Patient Podcast
Dr. Steffen-Sebastian Bolz, Chief Scientific Officer of Swiss-based Aphaia Pharma, shines a light on the excitement around weight loss drugs due to the discovery that GLP-1 agonists and points out the shift in the perception of obesity as a root cause of various health issues. Aphaia Pharma's approach involves stimulating hormone production in the small intestine by reinvigorating the mechanism that has become dormant due to the ingestion of highly refined foods. The company is also exploring the effects of the circadian rhythm on weight loss and maintaining a healthy weight. Steffen...
info_outline Healthcare Outcomes When Hospitals Embrace Vertical Farming with Rick Vanzura Freight Farms and Dr. Amber Orman Advent Health TRANSCRIPTEmpowered Patient Podcast
Rick Vanzura, CEO of Freight Farms, and Dr. Amber Orman, Chief Wellness Officer at Advent Health, discuss their partnership in bringing hyperlocal, sustainable food to healthcare facilities. Freight Farms uses modified shipping containers to grow crops, allowing for year-round production with minimal land and water usage. Advent Health recognized the importance of nutrition in whole-person care and saw the opportunity to provide their team members, physicians, patients, and the public with fresh, nutritious food and donate to local food pantries. The partnership has demonstrated the power of...
info_outline Healthcare Outcomes When Hospitals Embrace Vertical Farming with Rick Vanzura Freight Farms and Dr. Amber Orman Advent HealthEmpowered Patient Podcast
Rick Vanzura, CEO of Freight Farms, and Dr. Amber Orman, Chief Wellness Officer at Advent Health, discuss their partnership in bringing hyperlocal, sustainable food to healthcare facilities. Freight Farms uses modified shipping containers to grow crops, allowing for year-round production with minimal land and water usage. Advent Health recognized the importance of nutrition in whole-person care and saw the opportunity to provide their team members, physicians, patients, and the public with fresh, nutritious food and donate to local food pantries. The partnership has demonstrated the power of...
info_outlineMike Kelly, CEO of NervGen Pharma, discusses the company's vision to build a startup biotech focused on repairing the central nervous system, helping patients regain function, not just slowing progression. Their first product, NVG-291, is currently in clinical trials for spinal cord injury. The drug candidate aims to promote natural repair by targeting molecules called CSPGs that inhibit nerve growth and repair. NerveGen is also developing NVG-300 for other indications such as stroke, ALS, MS, and Alzheimer's. He draws parallels between his previous experience developing the Narcan Nasal Spray for opioid overdose and the unmet medical need in spinal cord injury.
Mike explains, "We are a company focusing on a group of products, more like a platform, that will enable the nervous system to repair itself. So the vision is to build a startup biotech focused in CNS and to get our first product over the line in spinal cord injury."
"There are no drugs available. So this is something that happens in an instant and someone's life has changed forever. The patient typically will then get hospitalized, have surgery to decompress the area that's injured, and then they're on the road to recovery. The only treatment is rehabilitation and exercise, and they push themselves to remake as many connections as possible. Still, that repair typically plateaus around six to nine months after their injury. And the level of function they regained during that period is where they'll be for the rest of their lives, unfortunately."
"NVG-291 is a product that aims to promote natural repair. When you damage, say, you cut your finger or break your foot, your body repairs itself very easily. When you damage your central nervous system, your body protects itself very well and inhibits repair, actually. Our drug targets one of those mechanisms that inhibit repair, turns it off, and allows the body to repair itself naturally."
#NervGenPharma #SCI #SpinalCordInjury #SpinalNews #SpinalInjury #Paralysis #NerveRepair #CNS